Top

Journal of Cancer Research and Clinical Oncology

Published in:

01-06-2011 | Original Paper

A literature-based meta-analysis taxane-based doublet versus single-agent taxane chemotherapy in patients with advanced breast cancer

Authors: Hong-Bin Xu, Qing Xu, Ling Li

Published in: Journal of Cancer Research and Clinical Oncology | Issue 6/2011

Abstract

Purpose

Clinical trials have reported conflicting results as to whether taxane-based doublet improves outcome over single-agent taxane in patients with advanced breast cancer.

Methods

We performed a meta-analysis comparing primary and secondary end points of taxane-based doublet with single-agent taxane chemotherapy in patients with advanced breast cancer and prior anthracycline treatment. The event-based relative risk ratio (RR) with 95% confidence intervals (95% CI) was derived, and a test of heterogeneity was applied.

Results

Four eligible trials (2,343 patients) were selected from 488 studies that initially were identified. A significant difference in favoring taxane-based doublet over single-agent taxane was observed in progression-free survival (PFS) (RR, 1.33; 95% CI, 1.02–1.75; P = 0.039) and partial response (PR) (RR, 1.43; 95% CI, 1.10–1.86; P = 0.008). The ORR was higher for patients receiving taxane-based doublet, although not statistically significant (RR, 1.17; 95% CI, 0.91–1.50; P = 0.220). Whereas there was no difference in 1-year survival rate (1-year SR) (RR, 1.05; 95% CI, 0.94–1.17; P = 0.422), clinical benefit (CB) (RR, 1.02; 95% CI, 0.95–1.09; P = 0.642), and complete response (CR) (RR, 0.75; 95% CI, 0.31–1.79; P = 0.512). Toxicities did not differ significantly except stomatitis and diarrhea.

Conclusion

Taxane-based doublet appeared to improve PFS and PR compared with single-agent taxane in the treatment of patients with advanced breast cancer. Further prospective, randomized, controlled trials will be necessary.

Aihara T, Kim Y, Takatsuka Y (2002) Phase II study of weekly docetaxel in patients with metastatic breast cancer. Ann Oncol 13:286–292PubMedCrossRef

Albain KS, Nag SM, Calderillo-Ruiz G, Jordaan JP, Llombart AC, Janusz Rolski AP, Melemed AS, Reyes-Vidal JM, Sekhon JS, Simms L, O’Shaughnessy J (2008) Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol 26:3950–3957PubMedCrossRef

Baltali E, Altundag K, Ozisik Y, Guler N, Tekuzman G (2004) Weekly paclitaxel in pretreated metastatic breast cancer: retrospective analysis of 52 patients. Tohoku J Exp Med 203:205–210PubMedCrossRef

Bergh J, Jonsson PE, Glimelius B, Nygren P (2001) A systematic overview of chemotherapy effects in breast cancer. Acta Oncol 40:253–281PubMedCrossRef

Bonneterre J, Roche H, Monnier A, Guastalla JP, Namer M, Fargeot P, Assadourian S (2002) Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure. Br J Cancer 87:1210–1215PubMedCrossRef

Bontenbal M, Creemers GJ, Braun HJ, de Boer AC, Janssen JT, Leys RB, Ruit JB, Goey SH, van der Velden PC, Kerkhofs LG, Schothorst KL, Schmitz PI, Bokma HJ, Verweij J, Seynaeve C (2005) Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a dutch community setting trial for the Clinical Trial Group of the Comprehensive Cancer Centre. J Clin Oncol 23:7081–7088PubMedCrossRef

Bria E, Giannarelli D, Felici A, Peter WP, Nistico C, Vanni B, Cuppone F, Cognetti F, Terzoli E (2005) Taxanes with anthracyclines as first-line chemotherapy for metastatic breast carcinoma. Cancer 103:672–679PubMedCrossRef

Bullock K, Blackwell K (2008) Clinical efficacy of taxane-trastuzumab combination regimen for HER-2-positive metastatic breast cancer. Oncologist 13:515–525PubMedCrossRef

Burstein HJ, Manola J, Younger J, Parker LM, Bunnell CA, Scheib R, Matulonis UA, Garber JE, Clarke KD, Shulman LN, Winer EP (2000) Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol 18:1212–1219PubMed

Case LD, Kimmick G, Paskett ED, Lohman K, Tucker R (2002) Interpreting measures of treatment effect in cancer clinical trials. Oncologist 7:181–187PubMedCrossRef

Chan S, Friedrichs K, Noel D, Pintér T, Van Belle S, Vorobiof D, Duarte R, Gil Gil M, Bodrogi I, Murray E, Yelle L, von Minckwitz G, Korec S, Simmonds P, Buzzi F, González Mancha R, Richardson G, Walpole E, Ronzoni M, Murawsky M, Alakl M, Riva A, Crown J (1999) Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 17:2341–2354PubMed

D’Hondt R, Paridaens R, Wildiers H, Pauwelyn K, Thomas J, Dumez H, Van O, Allan T (2004) Safety and efficacy of weekly docetaxel in frail and/or elderly patients with metastatic breast cancer: a phase II study. Anticancer Drugs 15:341–346PubMedCrossRef

DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188PubMedCrossRef

Di Leo A, Gomez HL, Aziz Z, Zvirbule Z, Bines J, Arbushites MC, Guerrera SF, Koehler M, Oliva C, Stein SH, Williams LS, Dering J, Finn RS, Press MF (2008) Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol 26:5544–5552PubMedCrossRef

Fountzilas G, Dafni U, Dimopoulos MA, Koutras A, Skarlos D, Papakostas P, Gogas H, Bafaloukos D, Kalogera-Fountzila A, Samantas E, Briasoulis E, Pectasides D, Maniadakis N, Matsiakou F, Aravantinos G, Papadimitriou C, Karina M, Christodoulou C, Kosmidis P, Kalofonos HP (2009) A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: a Hellenic Cooperative Oncology Group study. Breast Cancer Res Treat 115:87–99PubMedCrossRef

Fumoleau P, Seidman AD, Trudeau ME, Chevallier B, Huinink WWTB (1997) Docetaxel: a new active agent in the therapy of metastatic breast cancer. Expert Opin Investing Drugs 6:1853–1865CrossRef

Gennari A, Conte P, Rosso R, Orlandini C, Bruzzi P (2005) Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies. Cancer 104:1742–1750PubMedCrossRef

Gori S, Mosconi AM, Basurtol C, Cherubinil R, DeAngelis V, Tonato M, Colozza M (2002) Weekly paclitaxel in metastatic breast cancer patients: a phase II study. Tumori 88:470–473PubMed

Hainsworth JD, Burris HA, Yardley DA, Bradof JE, Grimaldi M, Kalman LA, Sullivan T, Baker M, Erland JB, Greco FA (2001) Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial. J Clin Oncol 19:3500–3505PubMed

Horiguchi J, Oyama T, Koibuchi Y, Yokoe T, Takata D, Ikeda F, Nagaoka H, Rokutanda N, Nagaoka R, Ishikawa Y, Odawara H, Kikuchi M, Sato A, Iino Y, Takeyoshi I (2009) Neoadjuvant weekly paclitaxel with and without trastuzumab in locally advanced or metastatic breast cancer. Anticancer Res 29:517–524PubMed

Icli E, Akbulut h, Uner A (2002) Paclitaxel (T) vs cisplatin + VP-16 (EP) in metastatic breast cancer patients treated with anthracyclines: a phase III randomized study. Turkish Oncology Group. Ann Oncol 13(Suppl 5):47

Icli F, Akbulut H, Uner A, Yalcin B, Baltali E, Altinbas M, Coşkun S, Komurcu S, Erkisi M, Demirkazik A, Senler FC, Sencan O, Büyükcelik A, Boruban C, Onur H, Zengin N, Sak SD (2005) Cisplatin plus oral etoposide (EoP) combination is more effective than paclitaxel in patients with advanced breast cancer pretreated with anthracyclines: a randomised phase III trial of Turkish Oncology Group. Br J Cancer 92:639–644PubMedCrossRef

Jackisch C, Eibach H, Knuth A (2000) Phase II trial of docetaxel weekly as dose dense treatment in metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 18:417a

Jensen BV (2006) Cardiotoxic consequences of anthracycline-containing therapy in patients with breast cancer. Semin Oncol 33(suppl 8):15–21CrossRef

Kuroi K, Bando H, Saji S, Toi M (2003) Protracted administration of weekly docetaxel in metastatic breast cancer. Oncol Rep 10:1479–1484PubMed

Lombardi D, Crivellari D, Scuderi C, Magri MD, Spazzapan S, Sorio R, DiLauro V, Scalone S, Veronesi A (2004) Long-term, weekly one-hour infusion of paclitaxel in patients with metastatic breast cancer: a phase II monoinstitutional study. Tumori 90:285–288PubMed

Maisano R, Mare M, Zavattieri M, Caristi N, Mesiti M, Scisca C, Latorre F (2003) Is weekly docetaxel an active and gentle chemotherapy in the treatment of metastatic breast cancer? Anticancer Res 23:1923–1926PubMed

Mey U, Gorschluter M, Ziske C, Kleinschmidt R, Glasmacher A, Schmidt-Wolf IGH (2003) Weekly docetaxel in patients with pretreated metastatic breast cancer: a phase II trial. Anticancer Drugs 14:233–238PubMedCrossRef

Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666–2676PubMedCrossRef

Nabholtz JM, Thuerlimann B, Bezwoda WR, Melnychuk D, Dounma J, Vandenberg TA, Rapoport B, Rosso R, Trillet Lenoir V, Drbal J, Aapro MA, Alaki M, Murawsky M, Allesandro R (1997) Docetaxel vs mitomycin plus vinblastine in anthracycline-resistant metastatic breast cancer. Oncology (Williston Park) 11(Suppl 8):25–30

Nabholtz JM, Senn HJ, Bezwoda W, Melnychuk D, Deschênes L, Douma J, Vandenberg TA, Rapoport B, Rosso R, Trillet-Lenoir V, Drbal J, Molino A, Nortier JW, Richel DJ, Nagykalnai T, Siedlecki P, Wilking N, Genot JY, Hupperets PS, Pannuti F, Skarlos D, Tomiak EM, Murawsky M, Alakl M, Aapro M (1999) Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol 17:1413–1424PubMed

O’Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G, Fumoleau P, Jones S, Lui WY, Mauriac L, Twelves C, Hazel GV, Verma S, Leonard R (2002) Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20:2812–2823PubMedCrossRef

Perez EA, Vogel CL, Irwin DH, Kirshner JJ, Patel R (2001) Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol 19:4216–4223PubMed

Ramos M, Gonzalez-Ageitos A, Amenedo M, Gonzalez-quintas A, Gamzo JL, Togores P, Losada G, Almanza C, Romero C, Gomez-martin C (2003) Weekly docetaxel as second-line therapy for patients with advanced breast cancer resistant to previous anthracycline treatment. J Chemother 15:192–197PubMed

Sato K, Inoue K, Saito T, Kai T, Mihara H, Okubo K, Koh J, Mochizuki H, Tabei T (2003) Multicenter phase II trial of weekly paclitaxel for advanced or metastatic breast cancer: the Saitama Breast Cancer Clinical Study Group (SBCCSG-01). Jpn J Clin Oncol 33:371–376PubMedCrossRef

Sawada N, Ishikawa T, Fukase Y et al (1998) Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by Taxol/Taxotere in human cancer xenografts. Clin Cancer Res 4:1013–1019PubMed

Seidman AD, Hudis CA, Albanel J, Tong W, Tepler I, Currie V, Moynaha ME, Theodoulou M, Gollub M, Baselga J, Norton L (1998) Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 16:3353–3361PubMed

Sjostrom J, Blomqvist C, Mouridsen H, Pluzanska A, Ottosson Lonn S, Bengtsson NO, Ostenstad B, Mjaaland I, Palm Sjovall M, Wist E, Valvere V, Anderson H, Bergh J (1999) Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer 35:1194–1201PubMedCrossRef

Sparano JA, Makhson AN, Semiglazov VF, Tjulandin SA, Balashova OI, Bondarenko IN, Bogdanova NV, Manikhas GM, Oliynychenko GP, Chatikhine VA, Zhuang SH, Xiu L, Yuan ZL, Rackoff WR (2009) Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: results from a randomized phase III study. J Clin Oncol 27:4522–4529PubMedCrossRef

Trudeau ME, Eisenhauer EA, Higgins BP, Letendre F, Lofters WS, Norris BD, Vandenberg TA, Delorme F, Muldal AM (1996) Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 14:422–428PubMed

Verma S, Maraninchi D, O’Shaughnessy J, Jamieson C, Jones S, Martin M, Mckendrick J, Miles D, Twelves C, Hornberger J (2005) Capecitabine plus docetaxel combination therapy. Cancer 103:2455–2465PubMedCrossRef

Verma S, Dent S, Chow BJ, Rayson D, Safra T (2008) Metastatic breast cancer: the role of pegylated liposomal doxorubicin after conventional anthracyclines. Cancer Treat Rev 34:391–406PubMedCrossRef

Von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, Rozencweig M, Muggia FM (1979) Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91:710–717

Wist EA, Sommer HH, Ostenstad B, Risberg T, Fjaestad K (2004) Weekly one-hour paclitaxel as first-line chemotherapy for metastatic breast cancer. Acta Oncol 43:11–14PubMedCrossRef

Title: A literature-based meta-analysis taxane-based doublet versus single-agent taxane chemotherapy in patients with advanced breast cancer
Authors: Hong-Bin Xu
Qing Xu
Ling Li
Publication date: 01-06-2011
Publisher: Springer-Verlag
Published in: Journal of Cancer Research and Clinical Oncology / Issue 6/2011
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-010-0967-8

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 6/2011

Association between age and synchronous liver metastasis in female colorectal cancer patients

The TNF-α, IL-1B and IL-10 polymorphisms and risk for hepatocellular carcinoma: a meta-analysis

Diabetes and prognosis in a breast cancer cohort

Breast cancer proteomics: a review for clinicians

Meta-analysis of the association between VEGF-634 G>C and risk of malignancy based on 23 case–control studies

The effect of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial: a meta-analysis of the US, German, Netherlands, and Belgium sub-studies

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials